Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.53 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 4/20 | 0.51 |
| ▸ | MGAM | O43451 | 3/20 | 0.51 |
| ▸ | SI | P14410 | 3/20 | 0.51 |
| ▸ | MGAM2 | Q2M2H8 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | STAT1 | P42224 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | XDH | P47989 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5505388 | 0.84 | XDH (0.48) | PDPK1LOXL2GAAMGAMSI | |
| SCHEMBL22531043 | 0.81 | HSPB1 (0.60) | PDPK1GAAMGAMSIMGAM2 | |
| SCHEMBL2311878 | 0.80 | MGAM (0.55) | PDPK1GAAMGAMSIMGAM2 | |
| SCHEMBL722198 | 0.80 | PDPK1 (0.77) | PDPK1LOXL2ALDH1A1RAB9AADRB2 | |
| SCHEMBL27853756 | 0.78 | ALDH1A1 (0.56) | PDPK1LOXL2GAAMGAMSI | |
| SCHEMBL1067139 | 0.78 | MAPT (0.60) | PDPK1LOXL2MAPTLMNAPOLB | |
| SCHEMBL27694793 | 0.76 | TDP1 (0.45) | GAAMAPTLMNANPC1MEN1 | |
| SCHEMBL28152442 | 0.76 | CYP19A1 (0.40) | PDPK1LOXL2GAAMGAMSI | |
| SCHEMBL27987415 | 0.76 | MAPT (0.45) | GAAMAPTLMNANPC1MEN1 | |
| SCHEMBL466424 | 0.75 | PDPK1 (0.63) | PDPK1LOXL2ADRB2HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0540143-B1 | Compounds and methods for inhibition of HIV and related viruses | MEDIVIR AB (SE) | 2003-02-05 | — | — | EP | claimed |
| US-5658907-A | THIOUREA VIRICIDES | MEDIVIR A/B (SE) | 1997-08-19 | — | — | US | claimed |
| EP-0540143-A2 | Compounds and methods for inhibition of HIV and related viruses | Medivir Aktiebolag (SE) | 1993-05-05 | — | — | EP | claimed |
| WO-1993003022-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1993-02-18 | — | — | WO | claimed |
| JP-6293746-A | — | — | None | — | — | JP | disclosed |
| CN-111263756-B | RAD51 inhibitors | 赛泰尔治疗公司 | 2023-05-16 | — | — | CN | disclosed |
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| CN-115677684-A | Substituted aryl or heteroaryl compounds | 先声药业有限公司 | 2023-02-03 | — | — | CN | disclosed |
| EP-3652159-B1 | SUBSTITUTED THIAZOLE DERIVATIVES AS RAD51 INHIBITORS FOR THE TREATMENT OF CANCER DISEASES, AUTOIMMUNE AND NEURODEGENERATIVE CONDITIONS | CYTEIR THERAPEUTICS INC (US) | 2023-01-18 | — | — | EP | disclosed |
| EP-3652159-B1 | SUBSTITUTED THIAZOLE DERIVATIVES AS RAD51 INHIBITORS FOR THE TREATMENT OF CANCER DISEASES, AUTOIMMUNE AND NEURODEGENERATIVE CONDITIONS | CYTEIR THERAPEUTICS INC (US) | 2023-01-18 | — | — | EP | disclosed |
| CN-115315423-A | Substituted aryl compounds | 先声药业有限公司 | 2022-11-08 | — | — | CN | disclosed |
| US-11291655-B2 | RAD51 inhibitors | CYTEIR THERAPEUTICS, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| WO-2006072953-A2 | RIGIDIFIED COMPOUNDS FOR MODULATING HEPARANASE ACTIVITY | INSIGHT BIOPHARMACEUTICALS LTD. (IL) | 2006-07-13 | — | — | WO | disclosed |
| CN-1337955-A | Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents | AMERICAN BAYER CORP (US) | 2002-02-27 | — | — | CN | disclosed |
| US-6197975-B1 | 7-AZABICYCLO(2.2.1)HEPTANE-7-CARBONYL-SUBSTITUTED 2-PHENYLINDOLE DERIVATIVES; SEXUAL DISORDERS; ANTICARCINOGENIC AGENTS | MERCK & CO. , INC. | 2001-03-06 | — | — | US | disclosed |
| CN-1209129-A | Antagonists of gonadotropin releasing hormone | MERCK & CO LTD (US) | 1999-02-24 | — | — | CN | disclosed |
| EP-0882040-A4 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO INC (US) | 1999-02-10 | — | — | EP | disclosed |
| EP-0882040-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | Merck & Co., Inc. (US) | 1998-12-09 | — | — | EP | disclosed |
| WO-1997021707-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1997-06-19 | — | — | WO | disclosed |
| JP-H06293746-A | PRODUCTION OF (ALKOXYCYANOPHENYL)THIAZOLE DERIVATIVE | TEIJIN LTD | 1994-10-21 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | RAD51, FANCI, BLM | PDPK1 1488/4885LOXL2 2883/4885GAA 4087/4885 |
| US-11291655-B2 | RAD51 inhibitors | RAD51, MRE11, SSBP1 | PDPK1 1241/4885LOXL2 3151/4885GAA 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.